There are still broad swaths of uncharted territories concerning the role lipid core plaques play in heart disease. Now, you can achieve unparalleled insights with the Infraredx Makoto Intravascular Imaging System, FDA-cleared for the detection of lipid core plaque (LCP) and the identification of patients and plaques with an increased risk of major adverse cardiovascular events (MACE). Anything else, and you are leaving valuable data on the table. For more information about the Makoto Imaging System and the accompanying Dualpro IVUS+NIRS Catheter or the OKAY II Y-Connector visit www.infraredx.com. Infraredx, a Nipro Company is an intravascular imaging company committed to advancing the diagnosis and management of coronary artery disease globally. Harnessing 30 years of research into the association between heart attacks and lipid-core plaques, Infraredx, a Nipro COmpany has been committed to the design, manufacture, and distribution of technologies that address the needs of practitioners and improve outcomes in the treatment of patients with coronary artery disease. With ongoing investment in several landmark global clinical trials, Infraredx’s mission, to enable cardiologists to predict heart attacks and prevent them, continues.
